The Myxo File Part I and II Reveals the FDA Compliance Review, Senate Finance Committee Investigation, Congressional and White House Communication to Help the Patients, and the 3-Agency Chart Summarizing the FDA, US Patent Office and the SEC Disclosures

The Myxo File Part I and II Reveals the FDA Compliance Review, Senate Finance Committee Investigation, Congressional and White House Communication to Help the Patients, and the 3-Agency Chart Summarizing the FDA, US Patent Office and the SEC Disclosures PR Newswire CHICAGO, December 20, 2012 CHICAGO, December 20, 2012 /PRNewswire/ -- - With Photo The FDA 510(k)